Effective May 12, 2026, Outlook Therapeutics canceled its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the "Prior Sales Agreement") with BTIG, LLC with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the "Prior ATM Program"). As a result of the termination of the Prior Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Prior ATM Program.